Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-09

Clinical Trial Update: RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RAD001 in non-clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RAD001 (everolimus)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED